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ABSTRACT/SUMMARY	  
Baseline	  clinical	  characteristics	  can	  be	  used	  to	  predict	  treatment	  
response	  in	  children	  with	  Attention	  Deficit	  and	  Hyperactivity	  Disorder	  
(ADHD).	  This	  analysis	  aimed	  to	  identify	  empirically	  derived	  subgroups	  of	  
children	  with	  ADHD	  based	  on	  likelihood	  of	  response	  to	  treatment	  within	  
the	  4	  randomly	  assigned	  treatment	  groups	  of	  the	  Multimodal	  Treatment	  
Study	  of	  Children	  with	  Attention-­‐Deficit/Hyperactivity	  Disorder	  (MTA).	  	  
To	  identify	  clinical	  characteristics	  of	  predictive	  value	  selected	  data	  
points	  were	  utilized	  for	  regression	  and	  receiver	  operating	  curve	  (ROC)	  
analysis.	  Response	  to	  treatment	  at	  14	  months	  (defined	  as	  a	  25-­‐30%	  
reduction	  in	  standardized	  score	  of	  symptoms	  obtained	  from	  the	  SNAP	  
scale)	  for	  each	  treatment	  group	  was	  utilized	  as	  the	  binary	  outcome	  for	  
ROC	  testing.	  The	  response	  rate	  in	  the	  4	  MTA-­‐delivered	  treatment	  arms	  
ranged	  from	  77%	  (medication	  management	  and	  combination	  treatment	  
groups)	  to	  60%	  in	  the	  behavioral	  treatment	  group.	  	  	  By	  comparison,	  the	  
response	  rate	  with	  community	  treatment	  was	  57%.	  	  	  
ROC	  analysis	  identified	  subgroups	  of	  children	  with	  very	  different	  
likelihoods	  of	  treatment	  response	  (ranging	  from	  18-­‐93%)	  using	  baseline	  
clinical	  characteristic.	  	  	  These	  differential	  response	  rates	  are	  useful	  to	  
identify	  patient	  subgroups	  that	  would	  most	  benefit	  from	  specific	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Established	  treatment	  modalities	  for	  Attention–Deficit/Hyperactivity	  
Disorder	  (ADHD)	  primarily	  include	  FDA-­‐approved	  medication	  (especially	  
stimulants)	  and	  behavioral	  therapy.	  With	  concerns	  for	  stimulant	  
treatment	  in	  children,	  variation	  in	  treatment	  practices,	  and	  few	  controlled	  
studies	  to	  guide	  the	  long-­‐term	  treatment	  of	  ADHD,	  in	  1992	  the	  National	  
Institute	  of	  Mental	  Health	  and	  Department	  of	  Education	  sponsored	  the	  
Multimodal	  Treatment	  Study	  of	  Children	  with	  ADHD	  (MTA).	  The	  MTA	  was	  
a	  multi-­‐site	  randomized	  clinical	  trial	  of	  579	  patients	  who	  were	  treated	  
with	  either	  careful	  medical	  management	  (MedMgt),	  multicomponent	  
behavioral	  therapy	  (Beh),	  MedMgt	  +	  Beh	  (Comb),	  or	  routine	  community	  
care	  (CC).	  Subjects	  were	  selected	  after	  careful	  assessment	  and	  diagnosis	  
of	  DSM-­‐IV	  ADHD	  Combined	  Type,	  and	  were	  not	  excluded	  for	  comorbid	  
disorders	  (oppositional-­‐defiant,	  conduct,	  and	  internalizing	  disorders	  or	  
specific	  learning	  disabilities)	  as	  long	  as	  the	  comorbidity	  was	  not	  
incompatible	  with	  study	  treatments.	  	  
	  
Children	  were	  randomly	  assigned	  to	  one	  of	  the	  four	  treatment	  groups.	  	  	  
Outcomes	  were	  assessed	  at	  baseline,	  3	  months,	  9	  months,	  and	  treatment	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endpoint	  of	  14	  months	  to	  measure	  relative	  effectiveness	  of	  each	  treatment	  
strategy	  (7).	  	  Random-­‐effects	  (mixed	  effects)	  regression	  was	  used	  
whenever	  possible	  for	  the	  intent-­‐to-­‐treat	  analysis,	  and	  outcome	  measures	  
were	  organized	  into	  6	  domains	  (ADHD	  symptoms,	  Aggression/ODD,	  
Internalizing	  symptoms,	  social	  skills,	  parent-­‐child	  relations,	  and	  academic	  
achievement)	  that	  were	  represented	  by	  a	  total	  of	  19	  measures.	  	  	  
	  
ADHD	  and	  oppositional/aggressive	  symptoms	  were	  measured	  with	  the	  
respective	  subscales	  of	  the	  parent-­‐	  and	  teacher-­‐completed	  Swanson,	  
Nolan,	  and	  Pelham	  (SNAP)	  Rating	  Scale	  (1).	  The	  SNAP	  contains	  18	  ADHD	  
and	  8	  Oppositional-­‐Defiant	  Disorder	  symptoms	  scored	  on	  a	  4-­‐point	  Likert	  
scale	  (0	  	  “not	  at	  all’	  to	  3	  “very	  much”)	  (1).	  The	  primary	  outcome	  of	  our	  
study	  (partial	  response	  to	  treatment	  criterion)	  was	  defined	  as	  a	  25-­‐30%	  
reduction	  in	  standardized	  score	  of	  symptoms	  (partial	  response)	  obtained	  
from	  the	  SNAP	  scale	  (2).	  This	  response	  criteria	  is	  different	  than	  those	  
employed	  in	  other	  studies,	  which	  limit	  response	  to	  “excellent	  responders”.	  	  
This	  measure	  was	  chosen	  to	  complement	  clinical	  interpretability	  of	  a	  
previous	  ROC	  analysis,	  which	  used	  “excellent	  response”	  (essentially	  a	  
remission	  criterion,	  a	  mean	  of	  1.0	  on	  the	  average	  of	  parent	  and	  teacher	  
SNAP)	  as	  the	  outcome	  measure	  (3).	  “Excellent	  response”	  (4)	  criterion	  
limit	  the	  interpretability	  of	  moderator	  subgroups	  to	  excellent	  responders.	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This	  narrows	  the	  range	  of	  applicability	  in	  treatment	  populations,	  and	  may	  
overlook	  some	  of	  the	  most	  at-­‐risk	  and	  difficult	  to	  treat	  children,	  who	  
show	  some	  improvement	  without	  achieving	  remission	  (3,	  5).	  Further,	  
prognostic	  information	  throughout	  treatment	  is	  still	  valuable	  for	  children	  
who	  do	  not	  reach	  full	  remission	  criteria,	  and	  again	  is	  especially	  important	  
for	  children	  whose	  initial	  symptoms	  are	  more	  severe	  (which	  is	  associated	  
with	  poorer	  outcomes,	  and	  lower	  likelihood	  of	  reaching	  full	  remission	  (3,	  
48,	  49).	  
	  
Meta-­‐analysis	  has	  previously	  demonstrated	  that	  psychostimulant	  
medications,	  several	  non-­‐psychostimulant	  medications	  and	  behavioral	  
interventions	  are	  effective	  treatments	  for	  ADHD	  over	  the	  short-­‐term	  (6-­‐
11).	  	  The	  MTA	  trial	  also	  demonstrated	  the	  superiority	  of	  the	  medication	  
management	  treatment	  strategy	  compared	  to	  behavioral	  treatment	  and	  
community	  care.	  	  The	  MTA	  primary	  analyses	  on	  separate	  domains	  found	  
that	  medication	  management	  alone	  was	  not	  significantly	  inferior	  to	  
combined	  treatment	  (with	  added	  behavioral	  intervention).	  	  However,	  
secondary	  analyses	  using	  composited	  measures	  (Swanson	  et	  al,	  2001;	  
Conners	  et	  al,	  2001)	  showed	  superiority	  of	  Comb	  over	  MedMgt	  by	  a	  small	  
effect	  size	  (d=0.28).	  A	  24-­‐month	  follow-­‐up	  with	  no	  further	  treatment	  by	  
the	  study	  found	  MedMgt	  and	  Comb	  still	  superior	  to	  Beh	  and	  CC,	  but	  by	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only	  half	  as	  much	  as	  at	  14	  months	  (MTA	  Cooperative	  Group,	  2004).	  The	  
MTA	  thus	  suggested	  that	  even	  over	  fairly	  long	  periods	  of	  time,	  (24	  
months),	  medication	  management	  appeared	  to	  be	  the	  most	  effective	  
intervention	  in	  reducing	  ADHD	  symptoms	  in	  the	  overall	  study	  population,	  
and	  that	  behavioral	  treatment	  provided	  little	  added	  benefit	  over	  
medications	  alone.	  	  
	  
	  Additionally,	  MTA	  trial	  results	  suggested	  a	  rational,	  evidence-­‐based	  
pharmacological	  approach	  to	  ADHD	  symptoms,	  which	  provided	  much	  
greater	  symptom	  improvement	  than	  the	  routine	  community	  
pharmacological	  management	  and	  behavioral	  treatment	  strategies.	  	  Based	  
on	  the	  MTA	  results,	  ADHD	  appears	  to	  be	  one	  of	  the	  few	  child	  psychiatric	  
conditions	  in	  which	  medication	  appears	  to	  work	  better	  than	  optimal	  
behavioral	  treatment	  strategies.	  
	  
The	  important	  findings	  from	  the	  MTA	  also	  extend	  far	  beyond	  the	  primary	  
findings	  of	  the	  trial.	  	  Several	  secondary	  MTA	  analyses	  have	  focused	  on	  
moderators	  of	  treatment	  effects.	  	  These	  secondary	  analyses	  examined	  
whether	  certain	  baseline	  patient	  characteristics	  (for	  example	  comorbid	  
clinical	  disorders,	  socioeconomic	  status	  and/or	  family	  factors)	  are	  
associated	  with	  treatment	  outcomes	  in	  study	  participants,	  and	  could	  thus	  
serve	  as	  “predictors”	  of	  treatment	  response.	  	  Secondary	  analysis	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demonstrated	  that	  in	  children	  with	  ADHD	  and	  comorbid	  anxiety	  disorders,	  
behavioral	  treatment	  was	  better	  than	  community	  care	  and	  very	  nearly	  
reached	  the	  efficacy	  of	  medication	  in	  parent	  reported	  ADHD	  
symptoms(12,	  13).	  	  	  	  
	  
Other	  secondary	  analyses	  of	  MTA	  trial	  data	  have	  associated	  family	  
income,	  parents’	  marital	  status,	  parental	  history	  of	  depression,	  
ineffective/negative	  parenting	  style,	  child	  IQ,	  complex	  comorbidities,	  
parental	  cognitions,	  and	  ethnicity	  with	  treatment	  outcomes	  (3,	  14-­‐18).	  
These	  analyses	  have	  clear	  implications	  for	  treatment	  approaches	  and	  
tailoring	  effective	  strategies	  to	  children	  who	  will	  benefit	  the	  most	  from	  
different	  interventions.	  
	  	  
The	  previously	  conducted	  moderator	  analyses	  of	  the	  MTA	  trial	  have	  
provided	  important	  information	  that	  can	  benefit	  the	  evidence-­‐based	  
treatment	  of	  children	  with	  Attention	  Deficit	  and	  Hyperactivity	  Disorder.	  	  
However,	  there	  are	  several	  reasons	  that	  moderator	  analyses	  could	  be	  
extended	  upon	  with	  a	  more	  integrated,	  data-­‐driven	  analysis.	  	  These	  
reasons	  include:	  (1)	  several	  baseline	  characteristics	  in	  the	  MTA	  trial	  have	  
not	  been	  examined	  as	  potential	  predictors	  or	  moderators	  of	  outcome;	  (2)	  
the	  relative	  clinical	  importance	  of	  implicated	  moderating	  variables	  still	  
remains	  unclear;	  and	  (3)	  interactions	  between	  potential	  moderating	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variables	  have	  not	  been	  fully	  explored.	  	  Our	  goal	  was	  to	  examine	  the	  
potential	  moderating	  effect	  of	  baseline	  characteristics	  associated	  with	  
treatment	  outcome	  using	  traditional	  logistic	  regression	  and	  receiver	  
operating	  curve	  (ROC)	  analysis.	  These	  analyses	  were	  performed	  within	  
each	  of	  the	  four	  treatment	  arms	  of	  the	  MTA	  data	  set.	  	  
	  
Receiver	  operating	  curve	  analysis	  has	  several	  advantages	  over	  regression	  
analyses	  in	  that:	  (1)	  Receiver	  operating	  curve	  allows	  for	  exploration	  of	  
higher-­‐order	  interactions	  between	  clinical	  variables	  and	  (2)	  is	  also	  
hypothesis	  independent.	  We	  will	  use	  ROC	  analysis	  to	  identify	  empirically	  
derived	  subgroups	  of	  children	  with	  ADHD	  who	  have	  similar	  likelihood	  of	  
response	  to	  treatment	  within	  each	  of	  the	  4	  treatment	  arms	  of	  the	  MTA	  
trial.	  	  	  
	  
Receiver	  Operating	  Curve	  analysis	  has	  been	  used	  for	  a	  wide	  range	  of	  
purposes,	  from	  evaluating	  medical	  tests	  (Kraemer	  HC.,	  1992)	  to	  utilizing	  
baseline	  clinical	  variables	  as	  predictors/moderators	  of	  treatment	  
response	  (19-­‐21).	  Also,	  as	  the	  analysis	  relies	  on	  binary	  outcomes	  
(response/non-­‐response)	  in	  order	  to	  identify	  subgroups	  with	  differential	  
prognosis	  (22),	  it	  is	  useful	  in	  generating	  empirically	  derived	  decision	  
trees	  for	  treatment(3,	  23).	  This	  is	  important	  to	  inform	  clinical	  treatment	  
by	  identifying	  who	  will	  benefit	  (and	  from	  which	  intervention),	  as	  well	  as	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potentially	  creating	  meaningful	  cutoff	  values	  necessary	  to	  guide	  public	  
policy	  decision-­‐making	  (24).	  These	  characteristics	  described	  also	  create	  
an	  opportunity	  for	  tailoring	  treatment	  based	  on	  subgroup	  characteristics	  
and	  likelihood	  for	  response	  to	  treatment.	  
	  
As	  the	  primary	  aim	  of	  this	  work	  is	  to	  identify	  subgroups	  of	  patients	  with	  
differential	  probability	  of	  response	  to	  treatment	  -­‐including	  how	  baseline	  
characteristics	  may	  interact	  to	  influence	  the	  likelihood	  of	  response-­‐	  ROC	  
analysis	  is	  a	  valuable	  addition	  to	  traditional	  regression	  analysis.	  	  ROC	  
analysis	  is	  sensitive	  to	  higher-­‐order	  interactions,	  and	  can	  evaluate	  a	  large	  
number	  of	  predictor	  variables	  and	  their	  interactions	  (with	  no	  issues	  of	  	  
multicollinearity).	  The	  ROC	  approach	  can	  also	  tolerate	  missing	  data	  from	  
one	  subject	  without	  losing	  the	  other	  data	  collected	  from	  that	  subject.	  	  
Finally,	  the	  cut	  points	  determined	  by	  the	  ROC	  approach	  are	  designed	  to	  
minimize	  false	  positives	  and	  false	  negatives,	  but	  allows	  for	  fine	  




STATEMENT	  OF	  PURPOSE	  
	  
	  
Optimization	  of	  treatment	  regimen	  and	  outcomes	  is	  an	  important	  part	  of	  
determining	  clinical	  course	  and	  navigating	  various	  treatment	  options.	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This	  is	  especially	  important	  when	  available	  treatment	  strategies	  include	  
the	  use	  of	  stimulant	  medications	  in	  pediatric	  populations,	  or	  resource-­‐
intensive	  behavioral	  interventions.	  	  
	  
Further,	  analysis	  of	  publically	  available	  MTA	  study	  data	  may	  allow	  for	  an	  
increased	  availability	  of	  prognostic	  data	  based	  on	  standardized	  treatment	  
regimens,	  and	  identification	  of	  subgroups	  of	  patients	  (based	  on	  baseline	  
clinical	  characteristics)	  who	  are	  most	  likely	  to	  benefit	  from	  various	  
treatment	  strategies.	  	  
	  
We	  hypothesize	  that	  (1)	  baseline	  clinical	  characteristics	  will	  predict	  
treatment	  response	  in	  children	  with	  ADHD	  and	  (2)	  informative	  baseline	  
clinical	  characteristics	  predicting	  treatment	  response	  will	  differ	  based	  on	  
treatment	  modality.	  The	  aim	  of	  this	  analysis	  is	  to	  identify	  empirically	  
derived	  subgroups	  of	  children	  with	  ADHD	  based	  on	  their	  likelihood	  of	  






Dr.	  Bloch	  acquired	  the	  MTA	  data	  set,	  and	  he	  supervised	  and	  advised	  us	  
throughout	  the	  process.	  My	  role	  was	  to	  review	  all	  variables	  collected	  for	  
the	  MTA	  trail,	  maintain	  documents	  and	  files	  of	  data	  and	  scales/measures,	  
compete	  an	  extensive	  literature	  search,	  define	  response	  variables,	  and	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evaluate	  the	  data	  generated	  from	  evaluation	  with	  the	  help	  of	  my	  research	  
advisor	  and	  Mr.	  Jakubovski.	  After	  my	  literature	  search	  variables	  were	  
selected	  based	  on	  previous	  studies	  showing	  relevance/predictive	  value.	  
Other	  variables	  were	  selected	  because	  they	  had	  not	  been	  reported	  in	  the	  
literature,	  and	  finally	  some	  were	  deemed	  worth	  inclusion	  after	  a	  
discussion	  of	  their	  clinical	  relevance	  or	  ease	  of	  baseline	  assessment.	  I	  was	  
also	  responsible	  for	  generating	  diagrams	  of	  relevant	  data. 	  
	  
Study	  Overview:	  	  
The	  rationale,	  design,	  aims,	  and	  methods	  of	  the	  MTA	  trial	  have	  been	  
described	  elsewhere	  (28-­‐30).	  All	  participants	  and	  their	  parents	  provided	  
informed	  consent	  (and	  assent).	  The	  National	  Institutes	  of	  Health	  as	  well	  
as	  the	  Institutional	  Review	  Boards	  at	  each	  of	  the	  clinical	  research	  sites	  
approved	  the	  research	  protocol.	  No	  additional	  ethics	  review	  processes	  
were	  required	  to	  access	  this	  data	  set.	  
	  
Subjects:	  	  
Five	  hundred	  seventy-­‐nine	  children	  were	  recruited.	  	  A	  detailed	  
description	  of	  the	  demographic	  and	  clinical	  characteristics	  of	  the	  subjects	  
in	  each	  treatment	  group	  can	  be	  found	  in	  the	  original	  MTA	  publication(30,	  
31).	  Subjects	  were	  recruited	  to	  represent	  a	  wide	  range	  of	  demographic	  
characteristics	  and	  comorbidities	  associated	  with	  Attention	  Deficit	  and	  
Hyperactivity	  Disorder.	  The	  selection	  aimed	  to	  create	  a	  representative	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sample	  of	  the	  children	  seen	  in	  clinical	  practice	  from	  all	  six	  sites	  across	  the	  
United	  States	  and	  Canada.	  To	  be	  included	  in	  the	  MTA	  trial	  subjects	  of	  
either	  sex	  were	  required	  to	  be	  between	  the	  ages	  of	  7	  and	  9.9	  	  (grades	  1-­‐4)	  
and	  in	  residence	  with	  the	  same	  primary	  caretaker	  for	  at	  least	  the	  last	  6	  
months	  and	  meet	  DSM-­‐IV	  criteria	  for	  ADHD	  Combined	  type,	  using	  the	  
Diagnostic	  Interview	  Schedule	  for	  Children	  (DISC	  version	  3.0)	  
supplemented	  with	  2	  teacher	  reported	  symptoms	  for	  children	  close	  to	  the	  
diagnostic	  threshold.	  	  
	  
	  Exclusion	  criteria	  included	  the	  inability	  to	  participate	  in	  all	  components	  
of	  the	  study	  (e.g.,	  hospitalization,	  if	  the	  child	  had	  a	  history	  of	  intolerance	  
to	  MTA	  medication,	  or	  non-­‐English	  speaking	  primary	  caretaker).	  	  Children	  
were	  also	  excluded	  if	  they	  required	  other	  treatments	  that	  were	  
incompatible	  with	  any	  of	  the	  four	  possible	  MTA	  treatment	  assignments	  
(for	  example,	  Bipolar	  Disorder,	  Tourette	  Syndrome,	  or	  any	  neuroleptic	  




Participants	  in	  the	  MTA	  study	  were	  assessed	  at	  their	  baseline,	  3	  months,	  9	  
months,	  and	  at	  14	  months.	  ADHD	  and	  oppositional/aggressive	  symptoms	  
were	  measured	  with	  the	  respective	  subscales	  of	  the	  parent-­‐	  and	  teacher-­‐
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completed	  Swanson,	  Nolan,	  and	  Pelham	  (SNAP)	  Rating	  Scale	  (1).	  The	  
SNAP	  is	  a	  standardized	  scale	  contains	  18	  ADHD	  and	  8	  Oppositional-­‐
Defiant	  Disorder	  symptoms	  scored	  on	  a	  4-­‐point	  Likert	  scale	  (0	  	  “not	  at	  all’	  
to	  3	  “very	  much”)	  (1).	  The	  primary	  outcome	  of	  our	  study	  (response	  to	  
treatment)	  was	  defined	  as	  a	  25-­‐30%	  reduction	  in	  standardized	  score	  of	  
symptoms	  obtained	  from	  the	  SNAP	  scale	  (2).	  
	  
Social	  skills	  and	  internalizing	  symptoms	  were	  assessed	  with	  the	  
corresponding	  subscales	  of	  the	  parent-­‐	  and	  teacher-­‐rated	  Social	  Skills	  
Rating	  System	  (SSRS)	  (32).	  Parent	  Child	  Relations	  were	  measured	  with	  a	  
parent	  child	  relationship	  questionnaire	  (33).	  Parent	  Practices	  were	  
assessed	  using	  the	  Alabama	  Parenting	  Questionnaire,	  specifically	  in	  the	  
domain	  of	  parental	  involvement	  (34).	  Internalizing	  and	  Externalizing	  
scores	  were	  collected	  with	  the	  Child	  Behavior	  Checklist	  (CBCL)	  (35).	  The	  
CPT	  Impulsivity	  score	  was	  used	  in	  the	  assessment	  of	  attention	  and	  
impulsivity	  (36).	  Child	  IQ	  was	  determined	  using	  the	  Wechsler	  Intelligence	  
Scale	  for	  children	  (37).	  Parent,	  teacher,	  and	  child	  ratings	  were	  
supplemented	  with	  blinded	  ratings	  of	  school	  observations.	  
	  
The	  Yale	  Global	  Tic	  Severity	  Scale	  (YGTSS)	  (both	  current	  and	  worst	  ever)	  
(38),	  Beck	  Depression	  Inventory	  (BDI)(39),	  and	  the	  multidimensional	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anxiety	  scale	  (40)	  were	  also	  collected	  as	  clinical	  variables.	  Behavior	  
Problems	  were	  recorded	  using	  self-­‐reported	  antisocial	  behavior.	  	  
	  
Behavioral	  problems	  that	  were	  recorded	  for	  study	  purposes	  included	  
property	  destruction,	  stealing,	  and	  physical	  aggression.	  The	  total	  score	  on	  
the	  Child	  behavior	  Checklist	  (CBCL)	  was	  recorded,	  acting	  as	  a	  measure	  of	  
social	  problems,	  and	  both	  internalizing	  and	  externalizing	  symptoms.	  The	  
Parent	  Rated	  Social	  Skills	  Rating	  System(32)	  also	  had	  a	  total	  score,	  with	  
subscales	  measuring	  cooperation,	  assertiveness,	  responsibility,	  social	  
conduct,	  internalizing	  and	  externalizing	  symptoms,	  and	  hyperactivity	  
(35).	  The	  SCID	  -­‐	  Antisocial	  Personality	  Scale	  –	  for	  Parents(41)	  also	  
recorded	  the	  history	  of	  Conduct	  Disorder	  and	  Antisocial	  Personality	  
Disorder,	  while	  the	  parent	  rated	  Aggression	  and	  Conduct	  Problems	  Scale	  
created	  from	  DSM-­‐IV	  checklists	  collected	  other	  measures	  of	  conduct	  
problems	  and	  aggression.	  	  	  
	  
Problems	  at	  school	  were	  measured	  with	  the	  number	  of	  days	  absent	  from	  
school	  in	  the	  previous	  12	  months,	  history	  of	  expulsions	  from	  school,	  use	  
of	  school	  services,	  special	  education	  received	  by	  the	  child	  and	  the	  
homework	  problem	  checklist(42).	  Parent-­‐Child	  relationship	  measures	  
were	  also	  collected,	  which	  included	  the	  Alabama	  Parenting	  Questionnaire	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parent-­‐rated	  discipline	  (inconsistent,	  harsh,	  appropriate),	  parental	  
involvement,	  supervision,	  and	  positive	  parenting	  (43).	  The	  parent	  and	  
child	  ratings	  from	  the	  Parent-­‐Child	  Relationship	  Questionnaire	  (33)	  
(including	  praise,	  parental	  rationale,	  shared	  decision	  making,	  
possessiveness/protectiveness,	  affection,	  quarreling,	  affection,	  pro-­‐social	  
behaviors,	  similarity,	  dominance,	  intimacy,	  physical	  punishment,	  
admiration	  (of	  and	  for	  parents	  both	  parents	  and	  children),	  nurturance,	  
companionship,	  and	  guilt	  induction)	  were	  also	  recorded	  in	  the	  study.	  	  
Additionally,	  parental	  variables	  including	  knowledge	  about	  behavioral	  
principles,	  parental	  expectations	  questionnaire	  (total	  expectation	  on	  child	  
obedience	  as	  rated	  by	  parents),	  and	  parenting	  stress	  index	  (PSI)	  
(defensive	  responding,	  parent	  distress,	  parent-­‐child	  dysfunction,	  




Participants	  were	  randomized	  to	  one	  of	  four	  treatment	  arms	  (medication	  
management,	  behavioral	  treatment,	  combined	  treatment	  with	  medication	  
management	  and	  behavioral	  treatment,	  and	  community	  care)	  for	  14	  
months.	  Each	  of	  these	  treatment	  arms	  was	  designed	  as	  a	  management	  
strategy	  that	  would	  be	  flexible	  to	  each	  patient’s	  unique	  and	  individual	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clinical	  needs	  throughout	  treatment.	  	  Full	  details	  regarding	  the	  treatment	  
received	  in	  each	  of	  these	  randomized	  treatment	  groups	  is	  defined	  
elsewhere	  (45,	  46).	  	  
	  
These	  treatment	  strategies	  were	  modeled	  after	  treatment	  strategies	  for	  
ADHD	  with	  previously	  well-­‐established	  efficacy.	  Behavioral	  treatment	  
included	  35	  sessions	  of	  integrated	  parent	  training	  (45,	  46),	  as	  well	  as	  
child-­‐focused	  treatments	  (an	  intensive	  child-­‐focused	  summer	  training	  
program)(47)and	  school	  based	  interventions	  that	  were	  integrated	  within	  
the	  participant’s	  school	  year.	  This	  treatment	  arm	  also	  included	  an	  
intensive	  child-­‐focused	  summer	  training	  program(47).	  To	  be	  consistent	  
with	  clinical	  practice,	  these	  treatments	  were	  tapered	  with	  the	  ultimate	  
goal	  of	  parent-­‐managed	  behavioral	  treatment.	  	  
	  
Medication	  management	  involved	  a	  28-­‐day	  double	  blind,	  placebo-­‐
controlled	  titration	  of	  methylphenidate	  hydrochloride	  with	  subsequent	  
monthly	  monitoring	  and	  algorithm	  guided	  dose	  adjustments.	  For	  subjects	  
not	  responding	  to	  methylphenidate,	  openly	  titrated	  amphetamine	  and	  
other	  medications	  were	  utilized.	  Combined	  treatment	  provided	  both	  the	  
behavioral	  treatment	  and	  medication	  management.	  Regular	  supervision	  of	  
pharmacotherapists	  and	  psychotherapists	  was	  emphasized	  to	  ensure	  
strict	  adherence	  to	  protocols	  across	  all	  sites.	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Subjects	  randomized	  to	  the	  community	  care	  arm	  of	  the	  MTA	  study	  did	  not	  
receive	  treatment	  from	  the	  MTA,	  but	  instead	  were	  provided	  an	  extensive	  
list	  of	  the	  local	  community	  mental	  health	  referral	  resources	  and	  their	  
initial	  study	  assessments.	  Data	  on	  the	  treatments	  received	  in	  the	  
community	  mental	  health	  resources	  was	  collected	  at	  each	  time	  point,	  with	  
most	  children	  (67.4%)	  receiving	  medication	  at	  some	  point.	  All	  6	  sites	  
were	  crossed	  with	  all	  treatment	  conditions,	  such	  that	  all	  interventions	  
were	  provided	  at	  all	  of	  the	  MTA	  trail	  sites.	  
	  
	  
Statistical	  Analysis:	  	  	  	  
	  
Data	  preparation	  was	  conducted	  using	  SAS	  version	  9.2	  and	  Microsoft	  
Excel.	  Both	  logistic	  regression	  models	  and	  signal	  detection	  methodology	  
were	  used	  to	  find	  the	  best	  prediction	  model.	  SAS	  was	  used	  for	  simple	  and	  
multiple	  logistic	  regression	  models.	  The	  ROC	  analysis	  was	  performed	  
using	  free	  software	  available	  online	  from	  Ruth	  O’Hara	  at	  Stanford	  
University	  (http://www.stanford.edu/~yesavage/ROC.html).	  Data	  utilized	  
in	  this	  study	  was	  obtained	  from	  the	  National	  Institute	  of	  Mental	  Health	  
MTA	  Data	  Set.	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Logistic	  regression	  models	  assessed	  the	  association	  of	  the	  demographic,	  
social,	  and	  clinical	  characteristics	  with	  response	  using	  change	  from	  
baseline	  on	  the	  SNAP	  total	  score	  as	  the	  outcome	  variable.	  Not	  
surprisingly,	  studies	  have	  found	  that	  increased	  initial	  severity	  of	  ADHD	  
symptoms	  is	  associated	  with	  worse	  treatment	  response	  (3,	  48,	  49).	  The	  
definition	  of	  response	  to	  treatment	  for	  this	  study	  was	  a	  reduction	  of	  25-­‐
30%	  in	  symptoms	  (as	  measured	  by	  the	  SNAP	  scale)	  at	  the	  end	  of	  14	  
months	  (2).	  As	  previously	  noted,	  this	  measure	  was	  chosen	  to	  extend	  
clinical	  interpretability	  to	  include	  partial	  responders.	  In	  contrast	  many	  
previous	  analyses	  have	  used	  full	  remission	  criteria	  or	  “excellent	  
responders”.	  	  
	  	  
First,	  all	  predictor	  variables	  were	  tested	  separately.	  Next,	  significant	  
predictors	  (p<.05)	  from	  the	  simple	  regression	  models	  were	  entered	  into	  a	  
backward	  step-­‐wise	  multiple	  logistic	  regression	  model	  to	  assess	  the	  
unique	  and	  independent	  contribution	  of	  these	  variables	  to	  the	  response	  
rate	  in	  each	  of	  the	  four	  treatment	  arms	  of	  the	  MTA	  trial.	  
	  
Receiver	  Operating	  Curve	  analysis	  was	  used	  as	  an	  alternative,	  non-­‐
parametric	  method	  that	  operates	  via	  recursive	  partitioning.	  It	  aims	  at	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identifying	  subgroups	  of	  children	  who	  have	  a	  differential	  probability	  of	  
achieving	  a	  particular	  binary	  outcome	  that	  have	  been	  defined	  (27).	  Across	  
all	  predictor	  variables,	  the	  cut-­‐off	  point	  that	  yields	  the	  best	  prediction	  is	  
then	  used	  to	  divide	  the	  total	  sample	  in	  two	  subsamples.	  	  The	  same	  
procedure	  is	  repeated	  systematically	  in	  each	  subsample	  again	  and	  again.	  
This	  iterative	  process	  continues	  until	  a	  subgroup	  contains	  less	  than	  ten	  
individuals	  or	  the	  group	  difference	  is	  not	  significant	  at	  an	  alpha	  level	  of	  
0.05.	  We	  also	  stopped	  the	  analysis	  at	  the	  three-­‐way	  interaction	  level.	  
Models	  were	  calculated	  for	  response	  and	  remission	  on	  all	  four	  scales	  as	  
the	  outcome	  variable.	  	  	  
	  
Both	  logistic	  regression	  and	  Receiver	  Operating	  Curve	  analysis	  were	  
conducted	  for	  each	  of	  the	  four	  treatment	  arms	  separately.	  Baseline	  
characteristics	  were	  entered	  as	  predictor	  variables	  into	  both	  models,	  
including	  demographic	  variables	  (age	  of	  the	  child,	  race,	  sex,	  and	  the	  size	  
of	  the	  city	  most	  lived	  in).	  Other	  baseline	  characteristics	  that	  were	  also	  
collected	  were	  related	  to	  both	  parents	  (if	  the	  data	  was	  available).	  
Variables	  such	  as	  parental	  welfare,	  employment	  status,	  educational	  
achievement,	  and	  income	  status	  were	  collected.	  Information	  about	  the	  
medical	  history	  of	  the	  mother	  and	  child	  (for	  example,	  neonatal	  history	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including	  pregnancy	  length,	  birth	  weight,	  nicotine	  exposure	  in	  utero),	  and	  
compliance	  (to	  medical	  and	  psychosocial	  treatment)	  was	  also	  recorded.	  	  
	  
Additionally,	  neuropsychological	  variables	  included	  continuous	  
performance	  task	  (CPT)	  which	  provides	  scores	  of	  impulsivity,	  inattention,	  
and	  dyscontrol	  (36),	  as	  well	  as	  the	  Wechsler	  Intelligence	  Scale	  For	  
Children	  score	  (37)	  (WISC	  III)	  measuring	  verbal,	  performance,	  and	  full	  
scale	  IQ	  were	  also	  collected.	  The	  parent	  version	  of	  the	  Diagnostic	  
Interview	  Schedule	  for	  Children	  (DISC)	  was	  used	  to	  provide	  information	  
regarding	  comorbid	  disorders.	  These	  comorbid	  disorders	  include	  anxiety	  
(both	  separation	  type	  and	  generalized),	  phobia	  (including	  simple	  and	  
social),	  panic	  disorder,	  tics	  (both	  chronic	  and	  transient),	  and	  depression.	  
Information	  regarding	  family	  of	  Attention	  Deficient	  and	  Hyperactivity	  
Disorder,	  alcohol	  abuse,	  drug	  abuse,	  tics,	  Tourette	  syndrome,	  anxiety,	  
depression,	  obsessive-­‐compulsive	  disorder,	  psychiatric	  hospitalization,	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Results:	  
The	  response	  rate	  across	  all	  of	  the	  MTA-­‐delivered	  treatment	  arms	  ranged	  
from	  a	  high	  of	  77%	  (medication	  management	  and	  combination	  treatment	  
groups)	  to	  a	  low	  of	  60%	  in	  the	  behavioral	  treatment	  group.	  	  	  By	  
comparison,	  the	  response	  rate	  with	  community	  treatment	  was	  57%.	  	  
Response	  rates	  in	  specific	  subgroups	  of	  patients	  are	  detailed	  below.	  
	  
	  
Combination	  Treatment:	  	  
	  
	  
Figure	  1	  depicts	  the	  empirically	  derived	  hierarchical	  prognostic	  
subgroups	  for	  response	  to	  combination	  (behavioral	  	  +	  pharmacologic)	  
treatment	  in	  the	  MTA.	  N=	  Total	  Number	  of	  Children	  in	  the	  group,	  
n=number	  of	  responders	  
	  
Across	  all	  predictor	  variables,	  the	  cut-­‐off	  point	  that	  yields	  the	  best	  
prediction	  (in	  this	  example	  Parent	  Admiration/Pride	  in	  the	  child,	  as	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reported	  by	  parent	  score	  of	  4)	  is	  then	  used	  to	  divide	  the	  total	  sample	  in	  
two	  subsamples	  (seen	  here	  as	  29	  children	  with	  a	  score	  of	  less	  than	  4,	  and	  
98	  with	  a	  score	  greater	  than	  or	  equal	  to	  4).	  	  The	  same	  procedure	  is	  
repeated	  systematically	  in	  each	  subsample	  (in	  this	  example	  with	  
compliance	  to	  treatment	  at	  14	  months	  and	  Parental	  Distress	  Scores)	  until	  
a	  subgroup	  contains	  less	  than	  ten	  individuals	  or	  the	  group	  difference	  is	  
not	  significant	  at	  an	  alpha	  level	  of	  0.05.	  
	  
The	  overall	  response	  to	  treatment	  in	  this	  combination	  treatment	  group	  
was	  77.2%.	  Baseline	  clinical	  characteristics	  were	  able	  to	  identify	  
subgroups	  with	  as	  low	  as	  a	  31.3%	  likelihood	  of	  responding	  to	  combination	  
treatment	  (parent	  admiration	  of	  child	  reported	  by	  parent	  as	  “somewhat”	  
or	  less,	  and	  also	  parents	  who	  believe	  their	  child	  is	  “about	  as	  difficult	  or	  
less”	  than	  expected)	  to	  as	  high	  as	  a	  92.3%	  likelihood	  of	  responding	  to	  
combination	  treatment	  (parent	  admiration	  of	  child	  reported	  by	  parent	  as	  
“somewhat”	  or	  less,	  and	  parents	  who	  believe	  their	  child	  is	  “about	  as	  or	  
more	  difficult	  than	  expected”).	  The	  most	  discriminative	  predictor	  of	  
response	  was	  the	  level	  of	  parent	  admiration/pride	  in	  child	  (as	  reported	  
by	  parent).	  [χ2	  (1,	  N=127)=7.34,	  p<.01].	  	  
	  
	   21	  
In	  logistic	  regression	  analysis	  (Table	  A)	  maternal	  (gestational)	  smoking	  
during	  pregnancy	  was	  associated	  with	  poor	  response	  to	  combination	  
treatment.	  
	  
Table	  A	  	  
Univariate	  Regression	  Analysis	  in	  MTA	  Combination	  






p	  Confidence Limits 
Mother smoked during 
pregnancy 




















Figure	  2	  depicts	  the	  empirically	  derived	  hierarchical	  prognostic	  
subgroups	  for	  response	  to	  medication	  management	  in	  the	  MTA	  Trial.	  	  
	  
Overall	  response	  to	  treatment	  in	  this	  group	  was	  77.4%.	  Baseline	  clinical	  
characteristics	  were	  able	  to	  identify	  subgroups	  with	  as	  low	  as	  47.1%	  
likelihood	  of	  responding	  to	  medication	  (Full	  scale	  IQ	  less	  than	  87)	  to	  as	  
high	  as	  a	  92.9%	  likelihood	  of	  responding	  to	  medication	  management	  (Full	  
scale	  IQ	  greater	  than	  or	  equal	  to	  87,	  parent-­‐rated	  companionship	  rated	  as	  
high,	  and	  a	  verbal	  IQ	  less	  than	  115).	  The	  most	  discriminative	  predictor	  of	  
response	  was	  the	  full	  scale	  IQ.	  [χ2	  (1,	  N=115)=10.5,	  p<.001].	  	  
	  
Baseline	  characteristics	  associated	  with	  poor	  response	  to	  medication	  
management	  in	  logistic	  regression	  analysis	  (Table	  B)	  included	  number	  of	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days	  the	  child	  was	  absent	  from	  school	  in	  the	  previous	  year,	  a	  family	  
history	  of	  incarceration,	  a	  household	  member	  receiving	  welfare,	  and	  self-­‐
identifying	  as	  black.	  The	  child’s	  perception	  that	  they	  shared	  more	  in	  
decision	  making	  with	  the	  parent	  was	  also	  associated	  with	  decreased	  
response	  to	  treatment.	  Multivariate	  regression	  analysis	  suggested	  that	  the	  
best-­‐fitting	  model,	  which	  accounted	  for	  9%	  of	  the	  variability	  in	  response	  
to	  treatment	  included	  child	  -­‐rated	  shared	  decision-­‐making.	  	  
	  
Table	  B	  








FH of Incarceration 0.383 0.148 0.992 0.048 
Any Part of Household on 
Welfare 
0.351 0.125 0.983 
0.0464 
Ethnicity Self-reported as Black 0.323 0.119 0.878 0.0267 
Shared Decision Making 0.578 0.365 0.917 0.02 
Absent days at school in last 12 
months 
0.593 0.361 0.973 
0.0386 
Multivariate	  Regression	  Analysis	  in	  Medication	  Treatment	  Arm	  
Shared decision making 0.567 0.351 0.918 0.0209 
Absent days at school in last 12 
months 














Figure	  3	  depicts	  the	  empirically	  derived	  hierarchical	  prognostic	  
subgroups	  for	  response	  in	  the	  behavioral	  management	  treatment	  group	  of	  
the	  MTA	  trial.	  	  
	  
Overall	  response	  to	  treatment	  in	  this	  group	  was	  found	  to	  be	  60.2%.	  
Baseline	  clinical	  characteristics	  were	  able	  to	  identify	  subgroups	  with	  as	  
low	  as	  29.2%	  likelihood	  of	  responding	  to	  behavioral	  treatment	  (CPT	  
Impulsivity	  score	  greater	  than	  or	  equal	  to	  15)	  to	  as	  high	  as	  a	  92.9%	  
likelihood	  of	  responding	  (CPT	  Impulsivity	  score	  less	  than	  15,	  parent	  rated	  
companionship	  as	  “somewhat”	  or	  greater,	  and	  a	  YGTSS	  rating	  of	  less	  than	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10).	  The	  most	  discriminative	  predictor	  of	  response	  was	  CPT	  Impulsivity	  
score	  [χ2	  (1,	  N=118)=12.1,	  p<.001].	  	  
	  
Baseline	  characteristics	  associated	  with	  poor	  response	  to	  behavioral	  
treatment	  in	  regression	  analysis	  (Table	  C)	  included	  being	  born	  premature,	  
higher	  CPT	  impulsivity	  score,	  and	  high	  scores	  of	  parent-­‐rated	  “nurturance	  
(Nurturance	  being	  how	  much	  parents	  help/show	  children	  how	  to	  
complete	  tasks)”.	  	  In	  the	  multivariate	  regression	  analysis	  nurturance	  and	  
CPTH	  Impulsivity	  scores	  account	  for	  9%	  of	  the	  variability	  in	  response	  to	  
treatment.	  	  	  
	  
Table	  C	  	  





p	  Confidence Limits 
Preterm Birth 2.965 1.015 8.658 0.047 
CPTH Total Impulsivity 
Score 
0.936 0.892 0.983 0.008 
Nurturance 0.6503 0.3297 3.8911 0.049 
Multivariate	  Regression	  Analysis	  in	  Behavioral	  Treatment	  Arm	  
CPTH Total Impulsivity 
Score 
0.938 0.891 0.987 
0.013 












Figure	  4	  displays	  the	  empirically	  derived	  hierarchical	  prognostic	  
subgroups	  for	  response	  to	  community	  treatment	  in	  the	  MTA.	  
	  	  
Overall	  response	  to	  treatment	  in	  this	  group	  was	  56.8%.	  Baseline	  clinical	  
characteristics	  were	  able	  to	  identify	  subgroups	  with	  as	  low	  as	  18%	  
likelihood	  of	  responding	  to	  community	  treatment	  (father	  is	  rarely	  
involved	  in	  daily	  matters	  (homework,	  conversation,	  friends),	  involvement	  
in	  delinquent	  or	  aggressive	  behaviors	  either	  absent	  or	  minimally	  present,	  
and	  a	  total	  social	  skills	  score	  less	  than	  47)	  to	  as	  high	  as	  a	  88.2%	  
likelihood	  of	  responding	  to	  community	  treatment	  (father	  is	  “sometimes”	  
involved	  in	  daily	  matters	  (homework,	  conversation,	  friends),	  involvement	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in	  delinquent	  or	  aggressive	  behaviors	  present	  (minimally	  or	  greater),	  and	  
a	  	  perception	  of	  how	  much	  child	  admires/respects	  parent	  -­‐rated	  by	  
parent-­‐	  as	  between	  somewhat	  and	  hardly	  at	  all).	  The	  most	  discriminative	  
predictor	  of	  response	  was	  the	  level	  of	  paternal	  involvement	  (as	  reported	  
by	  child).	  [χ2	  (1,	  N=125)=12.5,	  p<.001].	  	  
	  
Baseline	  characteristics	  associated	  with	  response	  to	  community	  treatment	  
in	  logistic	  regression	  analysis	  include	  parental	  factors.	  Paternal	  
Involvement	  was	  associated	  with	  increased	  response	  to	  community	  
treatment.	  “Rationale”	  (i.e.,	  the	  degree	  to	  which	  parents	  explain	  why	  they	  
create	  certain	  rules	  and	  deliver	  punishment	  as	  rated	  by	  children)	  was	  
associated	  with	  decreased	  response	  to	  treatment.	  	  	  Multivariate	  
regression	  analysis	  including	  these	  two	  variables	  explained	  just	  over	  5%	  
of	  the	  variability	  in	  response	  to	  community	  treatment.	  	  	  	  	  	  
Table	  D	  








Involvement of Father in Child’s 
Life 
1.069 1.01 1.131 
0.022 
Rationale 0.716 0.513 0.998 0.049 
Multivariate	  Regression	  in	  Community	  Treatment	  Arm	  
Involvement of Father in Child’s 
Life 
1.087 1.021 1.157 
0.009 
Rationale 0.64 0.42 0.975 0.038 
R-Square 0.0522 
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Discussion:	  	  	  
	  
Empirically-­‐driven	  moderator	  analysis	  of	  the	  MTA	  trial	  data	  revealed	  
several	  important	  findings	  regarding	  treatment	  prognosis	  in	  childhood	  
ADHD.	  	  These	  findings	  included:	  	  
(1)	  Using	  baseline	  characteristics	  Receiver	  Operating	  Curve	  analysis	  
identified	  subgroups	  of	  children	  with	  very	  different	  likelihoods	  of	  
treatment	  response	  (ranging	  from	  18-­‐93%)	  which	  is	  useful	  to	  
prognosticate	  and	  identify	  patient	  subgroups	  that	  would	  most	  benefit	  
from	  specific	  treatment	  strategies.	  	  	  
(2)	  Predictor	  of	  treatment	  outcome	  were	  not	  consistent	  across	  the	  
different	  treatment	  arms	  of	  the	  MTA	  trial.	  	  As	  a	  rule,	  more	  biologically-­‐
based	  causes	  and	  measures	  of	  ADHD	  (CPT	  impulsivity	  score,	  prematurity)	  
were	  most	  useful	  in	  predicting	  response	  to	  behavioral	  treatment	  while	  
socioeconomic	  factors	  were	  more	  useful	  in	  predicting	  response	  to	  
medication	  management	  or	  community	  treatment,	  which	  was	  mainly	  
medication.	  
(3)	  Measures	  examining	  characteristics	  of	  the	  parent-­‐child	  relationship	  
(e.g.,	  paternal	  involvement,	  Alabama	  parenting	  scale	  subscores	  (43)	  )	  
were	  quite	  informative	  in	  predicting	  treatment	  outcome	  ,	  although	  the	  
specific	  informative	  measures	  	  were	  not	  consistent	  across	  treatment	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groups.	  	  (4)	  Several	  baseline	  characteristics	  previously	  identified	  as	  risk	  
factors	  for	  ADHD	  –	  maternal	  smoking	  and	  prematurity-­‐	  were	  also	  
associated	  with	  treatment	  outcome	  in	  specific	  MTA	  treatment	  groups.	  	  
	  
Maternal	  smoking	  and	  prematurity	  have	  been	  associated	  in	  many	  previous	  
studies	  with	  risk	  of	  ADHD	  (50,	  51).	  This	  study	  extends	  those	  results	  by	  
showing	  maternal	  smoking	  during	  pregnancy	  decreases	  the	  likelihood	  of	  
response	  to	  combination	  treatment.	  In	  a	  similar	  manner,	  prematurity	  was	  
associated	  with	  response	  rate	  in	  the	  behavioral	  treatment.	  Apparently	  
these	  putative	  biological	  causes	  predict	  poor	  response	  to	  behavioral	  
treatment.	  	  	  
	  
In	  addition	  to	  prematurity,	  more	  biologically	  based	  measures	  predicted	  
outcomes	  to	  behavioral	  treatment.	  Neuropsychological	  variables	  including	  
the	  CPT	  Impulsivity	  Score	  and	  IQ	  were	  moderating	  variables	  in	  2	  
treatment	  arms	  (in	  the	  behavioral	  and	  medication	  management	  groups,	  
respectively).	  	  IQ	  has	  also	  been	  found	  to	  be	  a	  moderator	  of	  response	  in	  
other	  studies,	  both	  in	  the	  MTA	  (3)	  and	  in	  earlier	  drug	  studies(52).	  In	  the	  
Behavioral	  treatment	  group	  the	  CPT	  Impulsivity	  score	  -­‐considered	  an	  	  
	   30	  
objective	  marker	  for	  impulsivity	  which	  has	  gained	  popularity	  since	  the	  
1950’s	  as	  a	  research	  tool-­‐	  was	  associated	  with	  poorer	  outcomes	  (53,	  54).	  	  	  
	  
In	  contrast	  to	  behavioral	  treatment,	  socioeconomic	  variables	  were	  
associated	  with	  response	  in	  medication	  groups	  (community	  and	  
pharmacotherapy).	  	  Welfare,	  a	  family	  history	  of	  incarceration,	  and	  self-­‐
identifying	  as	  black	  were	  associated	  with	  poorer	  outcomes	  in	  this	  study.	  
Prevalence	  of	  ADHD	  has	  been	  reported	  to	  be	  higher	  in	  socioeconomically	  
disadvantaged	  groups	  (55).	  The	  mechanism	  for	  the	  linkage	  of	  lower	  SES	  
and	  development	  of	  ADHD	  is	  not	  completely	  clear,	  though	  there	  is	  
literature	  providing	  alternative	  explanations	  and	  evidence	  (56).	  It	  is	  clear	  
from	  our	  analysis	  that	  these	  socioeconomic	  factors	  are	  also	  associated	  
with	  lower	  likelihood	  to	  respond	  to	  medication	  alone.	  This	  is	  compatible	  
with	  a	  previous	  MTA	  finding	  that	  minority	  children	  (who	  tend	  to	  be	  
disadvantaged),	  but	  not	  non-­‐Latino	  white	  children,	  benefit	  more	  from	  
Comb	  than	  from	  MedMgt	  (57).	  
	  
This	  moderator	  analysis	  also	  suggests	  that	  parent	  child	  relationships	  have	  
particularly	  important	  predictive	  value	  in	  ADHD.	  Further	  study	  is	  
required	  to	  understand	  mechanisms	  of	  these	  effects	  (58,	  59).	  Paternal	  
involvement,	  which	  was	  a	  good	  indicator	  of	  response	  in	  the	  community	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treatment	  group,	  also	  emerged	  in	  the	  regression	  analysis.	  	  There	  is	  much	  
room	  in	  the	  literature	  to	  better	  understand	  paternal	  involvement	  in	  the	  




These	  results	  suggest	  that	  greater	  parental	  pride	  in	  the	  child	  (as	  reported	  by	  
the	  parent)	  predict	  a	  good	  combination	  treatment	  response.	  Also	  “organic”	  
etiologies	  (prematurity,	  gestational	  smoke	  exposure)	  and	  impulsivity	  
interfere	  with	  the	  efficacy	  of	  behavioral	  treatment.	  	  Low	  IQ,	  much	  absence	  
from	  school,	  and	  child	  sharing	  in	  decision-­‐making	  (which	  may	  suggest	  a	  lack	  
of	  home	  structure)	  predict	  poor	  medication	  response.	  Finally	  a	  predictor	  of	  





The	  results	  of	  this	  analysis	  require	  replication	  because	  prognostic	  
subgroups	  were	  empirically	  derived	  without	  hypotheses.	  However,	  even	  
with	  empirically	  derived	  subgroups,	  ROC	  analysis	  has	  the	  distinct	  
advantage	  of	  analyzing	  higher	  order	  interactions	  between	  easily	  
measurable	  baseline	  clinical	  characteristics.	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Another	  limitation	  is	  the	  sample	  size	  of	  the	  MTA	  trial,	  which	  was	  designed	  
to	  be	  large	  enough	  to	  have	  adequate	  power	  to	  set	  the	  lower	  limit	  of	  
clinical	  significance	  as	  an	  effect	  size	  of	  .4	  and	  80%	  power	  (5%	  level	  of	  
confidence),	  but	  not	  necessarily	  designed	  to	  power	  the	  generation	  of	  
prognostic	  subgroups	  and	  moderator	  identification.	  	  
	  
Other	  limitations	  of	  this	  paper	  stem	  from	  -­‐and	  are	  shared	  with-­‐	  the	  
original	  MTA	  Study..	  Other	  limitations	  that	  are	  secondary	  to	  data	  
collection	  methods	  of	  the	  original	  paper	  include	  post-­‐treatment	  
evaluation	  of	  medication-­‐managed	  children	  (while	  they	  were	  actively	  
medicated)	  versus	  4-­‐6	  months	  after	  fading	  of	  Beh	  began.	  	  (61).	  However,	  a	  
finer-­‐grained	  comparison	  of	  the	  9-­‐	  and	  14-­‐month	  assessments	  found	  that	  
the	  Beh	  group	  actually	  improved	  more	  between	  the	  9-­‐month	  assessment,	  
at	  the	  end	  of	  intense	  behavioral	  treatment,	  and	  the	  14-­‐month	  assessment,	  
confirming	  that	  the	  fading/generalization	  procedures	  were	  successful	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